← FDA DRUG APPROVALS

FDA NDA · NDA011870

DIURIL

chlorothiazide

Sponsor: SALIX PHARMS

APPLICATION
NDA011870
TYPE
NDA
ORIGINAL APPROVAL
1961-10-06
LATEST ACTION
2009-06-10
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Discontinued

Products

DIURIL · ReferenceDiscontinued
CHLOROTHIAZIDE 250MG/5ML · SUSPENSION · ORAL

Approval history

2009-06-10Labeling · Supplement 40 · standardLabelAP
2009-04-02Manufacturing (CMC) · Supplement 41AP
2007-08-06Labeling · Supplement 39 · standardLetterAP
2005-08-10Labeling · Supplement 37 · standardLetterAP
2004-09-23Labeling · Supplement 36 · standardLetterAP
2002-09-26Manufacturing (CMC) · Supplement 35 · standardAP
2001-04-12Manufacturing (CMC) · Supplement 33 · standardAP
2000-02-25Manufacturing (CMC) · Supplement 32 · standardAP
1998-12-09Labeling · Supplement 31 · standardAP
1995-05-23Labeling · Supplement 30 · standardAP
1994-02-16Labeling · Supplement 29AP
1993-03-02Labeling · Supplement 27AP
1987-05-08Labeling · Supplement 19AP
1986-01-13Labeling · Supplement 23AP
1985-11-04Labeling · Supplement 22AP
1984-08-28Labeling · Supplement 21AP
1984-03-06Labeling · Supplement 20AP
1981-01-13Labeling · Supplement 18AP
1979-10-31Labeling · Supplement 14AP
1979-10-31Labeling · Supplement 17AP
1979-10-31Labeling · Supplement 15AP
1979-07-13Labeling · Supplement 16AP
1978-07-31Labeling · Supplement 13AP
1975-03-27REMS · Supplement 6 · standardAP
1961-10-06Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →